Drug Research
Gene Therapy By Bluebird Bio Costing $2.8M Given Nod By FDA
Gene therapy for blood disorders developed by Bluebird Bio has already left the nest in the US.
Zynteglo, sometimes known as betibeglogene autotemcel (beti-cel), was authorised by the FDA on August 17, two days before the FDA's scheduled approval action...
Drug Research
ADCs Built On Starpharma Delivery Tech To Be Tested By Merck
As it works to expand its antibody-drug conjugate (ADC) capabilities, Merck has strengthened its links to Starpharma by signing a second partnership that will allow it to assess potential candidates using a dendrimer drug delivery technology.
Merck and Starpharma agreed...
Drug Research
After Roe, Bayer Engages Lobbyists For Contraception Access
While a large portion of the biopharma industry prepares for a battle over medication prices, Bayer is getting ready for a different lobbying push of its own.
A disclosure form reveals that Bayer has hired a team of lobbyists to...
Drug Research
Trodelvy Wins A Battle Against Breast Cancer With Gilead
Gilead staked money on Trodelvy providing a life-extension benefit when it failed to show promise in halting tumour development in HR-positive HER2-negative breast cancer. Now that the drugmaker has unexpectedly returned with that victory, industry observers are still unconvinced.
According...
Drug Research
Study Uncovers And Exploits Flaws In Some High-Risk Cancers
A team of researchers led by C. Patrick Reynolds, M.D., Ph.D., director of the Texas Tech University Health Sciences Center (TTUHSC) School of Medicine Cancer Center, sought to build on earlier findings from his lab that showed ALT tumours...
Drug Research
Nasal Administration Could Boost HIV And COVID-19 Vaccines
A team led by an assistant professor from the University of Minnesota in the USÂ has created a new method to successfully administer vaccines through the mucosal tissues in the nose, which could result in improved defence against pathogens like...
Drug Research
Enhertu From AZ, Daiichi Sankyo Now Has The FDA Approval
With two significant FDA clearances in as many weeks, Enhertu from AstraZeneca and Daiichi Sankyo is blazing.
On August 11th, the medication obtained rapid approval for use in people with non-small cell lung cancer (NSCLC) that has the HER2 mutation...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
